Clinical study on Cidan Capsules combined with mFOLFOX6 regimen in treatment of Bismuth-Corlette Ⅱ hilar cholangiocarcinoma

Dong TAN,Kang ZHENG,Gang LIANG,Chao HAN,Qi-liang LI,Nai-ying SHEN,Meng-guo HE,Zhi-xiang WANG
DOI: https://doi.org/10.7501/j.issn.1674-5515.2019.04.043
2019-01-01
Abstract:Objective To study the clinical effects of Cidan Capsules combined with mFOLFOX6 regimen in treatment of Bismuth-Corlette Ⅱ hilar cholangiocarcinoma. Methods Patients (82 cases) with Bismuth-Corlette Ⅱ hilar cholangiocarcinoma in NO.215 Hospital of Shaanxi Nuclear Industry from January 2010 to January 2014 were randomly divided into control and treatment groups, and each group had 41 cases. Patients in the control group were iv administered with 5-Fluorouracil Injection on the first day, 2 800 mg/m2 for 4 — 6 h, as well as iv administered with Calcium Folinate Injection 400 mg/m2, and with Oxaliplatin Injection85 mg/m2 added into 5% glucose solution 500 mL for 3 h. Patients in the treatment group were po administered with Cidan Capsules on the basis of the control group, 5 grains/time, four times daily. Two weeks was a course of treatment, and patients in two groups were treated for 6 courses. After treatment, the short-term and long-term efficacy was evaluated, and the immune function, life quality and adverse actions in two groups before and after treatment were compared. Results After treatment, the objective reaction rate and clinical benefit rate in the control group were 73.1% and 50.9%, which were significantly lower than 81.7% and 62.5% in the treatment group, respectively, and there were differences between two groups (P<0.05). After treatment, the survival rate of 1 year, 2 years, and 3 years, and OS in the treatment group were significantly higher than those in the control group (P<0.05). After treatment, the CD3+, CD4+, IgG, IgA and IgM levels in two groups were significantly increased (P<0.05), and the immune function in the treatment group was significantly better than that in the control group (P<0.05). After treatment for 5 and 6 courses of treatment, the KPS scores in control group were significantly higher than pretherapy (P<0.05). After treatment for 3, 4, 5, and 6 courses of treatment, the KPS scores in treatment group were significantly higher than pretherapy (P<0.05), and were significantly higher than that in the control group (P<0.05). During the treatment, the adverse reactions rate in the treatment group was significantly lower than that in the control group, with significant difference between two groups (P<0.05). Conclusions Cidan Capsules combined with m FOLFOX6 regimen in treatment of Bismuth-Corlette Ⅱ hilar cholangiocarcinoma can improve the immune function, lengthen the survival time and decrease the toxic and side effects.
What problem does this paper attempt to address?